Mutations in FGFR3 have been reported in bladder cancer to be associated with a less-aggressive disease, lower-stage tumors, and improved prognosis, consistent with the data from our study [36, 38]. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.